Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report a case of rifampicin resistant Mycobacterium tube...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Willy Ssengooba, Kevin Komakech, Sharon Namiiro, Henry Byabajungu, Joanitah Nalunjogi, Winceslaus Katagira, Ivan Kimuli, Moses L Joloba, Susan Adakun, Lydia Nakiyingi, Gabriela Torrea, Bruce J Kirenga
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	XpertMTB/RIF G4 ULTRA Rifampicin Discordance Diseases of the respiratory system RC705-779 Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/2089ea3e49994b73aa467bc594eb9ba4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2089ea3e49994b73aa467bc594eb9ba4
record_format	dspace
spelling	oai:doaj.org-article:2089ea3e49994b73aa467bc594eb9ba42021-11-12T04:42:17ZRifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda2405-579410.1016/j.jctube.2021.100286https://doaj.org/article/2089ea3e49994b73aa467bc594eb9ba42021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2405579421000759https://doaj.org/toc/2405-5794Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.Willy SsengoobaKevin KomakechSharon NamiiroHenry ByabajunguJoanitah NalunjogiWinceslaus KatagiraIvan KimuliMoses L JolobaSusan AdakunLydia NakiyingiGabriela TorreaBruce J KirengaElsevierarticleXpertMTB/RIFG4ULTRARifampicinDiscordanceDiseases of the respiratory systemRC705-779Infectious and parasitic diseasesRC109-216ENJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 25, Iss , Pp 100286- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	XpertMTB/RIF G4 ULTRA Rifampicin Discordance Diseases of the respiratory system RC705-779 Infectious and parasitic diseases RC109-216
spellingShingle	XpertMTB/RIF G4 ULTRA Rifampicin Discordance Diseases of the respiratory system RC705-779 Infectious and parasitic diseases RC109-216 Willy Ssengooba Kevin Komakech Sharon Namiiro Henry Byabajungu Joanitah Nalunjogi Winceslaus Katagira Ivan Kimuli Moses L Joloba Susan Adakun Lydia Nakiyingi Gabriela Torrea Bruce J Kirenga Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
description	Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.
format	article
author	Willy Ssengooba Kevin Komakech Sharon Namiiro Henry Byabajungu Joanitah Nalunjogi Winceslaus Katagira Ivan Kimuli Moses L Joloba Susan Adakun Lydia Nakiyingi Gabriela Torrea Bruce J Kirenga
author_facet	Willy Ssengooba Kevin Komakech Sharon Namiiro Henry Byabajungu Joanitah Nalunjogi Winceslaus Katagira Ivan Kimuli Moses L Joloba Susan Adakun Lydia Nakiyingi Gabriela Torrea Bruce J Kirenga
author_sort	Willy Ssengooba
title	Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_short	Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_full	Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_fullStr	Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_full_unstemmed	Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_sort	rifampicin susceptibility discordance between xpert mtb/rif g4 and xpert ultra before mdrt-tb treatment initiation: a case report from uganda
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/2089ea3e49994b73aa467bc594eb9ba4
work_keys_str_mv	AT willyssengooba rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT kevinkomakech rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT sharonnamiiro rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT henrybyabajungu rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT joanitahnalunjogi rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT winceslauskatagira rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT ivankimuli rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT mosesljoloba rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT susanadakun rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT lydianakiyingi rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT gabrielatorrea rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda AT brucejkirenga rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
_version_	1718431218034278400

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

Ejemplares similares